Search

Your search keyword '"Navitsky, Michael"' showing total 138 results
Start Over Author "Navitsky, Michael"
138 results on '"Navitsky, Michael"'

3. Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study

Author

Pontecorvo, Michael J., Keene, C. Dirk, Beach, Thomas G., Montine, Thomas J., Arora, Anupa K., Devous, Sr, Michael D., Navitsky, Michael, Kennedy, Ian, Joshi, Abhinay D., Lu, Ming, Serrano, Geidy E., Sue, Lucia I., Intorcia, Anthony J., Rose, Shannon E., Wilson, Angela, Hellstern, Leanne, Coleman, Natalie, Flitter, Matthew, Aldea, Patricia, Fleisher, Adam S., Mintun, Mark A., and Siderowf, Andrew

Published
2020
Full Text
View/download PDF

11. Additional file of Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study

Author

Pontecorvo, Michael J., C. Dirk Keene, Beach, Thomas G., Montine, Thomas J., Anupa K. Arora, Devous, Michael D., Navitsky, Michael, Kennedy, Ian, Abhinay D. Joshi, Lu, Ming, Geidy E. Serrano, Sue, Lucia I., Intorcia, Anthony J., Rose, Shannon E., Wilson, Angela, Hellstern, Leanne, Coleman, Natalie, Flitter, Matthew, Aldea, Patricia, Fleisher, Adam S., Mintun, Mark A., and Siderowf, Andrew

Abstract

Additional file of Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study

Published
2020
Full Text
View/download PDF

12. Additional file 1 of Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study

Author

Pontecorvo, Michael J., C. Dirk Keene, Beach, Thomas G., Montine, Thomas J., Anupa K. Arora, Devous, Michael D., Navitsky, Michael, Kennedy, Ian, Abhinay D. Joshi, Lu, Ming, Geidy E. Serrano, Sue, Lucia I., Intorcia, Anthony J., Rose, Shannon E., Wilson, Angela, Hellstern, Leanne, Coleman, Natalie, Flitter, Matthew, Aldea, Patricia, Fleisher, Adam S., Mintun, Mark A., and Siderowf, Andrew

Subjects
nervous system, mental disorders, psychological phenomena and processes
Abstract

Additional file 1: Supplemental Figure 1. Example of PET ROI hand drawn to match pathology sample block, in this case right amygdala. Note the PET image is in radiologic orientation so the relevant ROI for this example is on the left of the image (blue). Supplemental Figure 2. Correlation between regional flortaucipir SUVr and Histelide estimate of regional Ptau in individual subjects. Blue symbols, regression line and Pearson’s r are for cortical regions. Green symbols reflect limbic regions: hippocampus/entorhinal cortex and amygdala. Red symbols represent subcortical regions: caudate/putamen, basal ganglia/nucleus basalis, thalamus. Supplementary Table.

Published
2020
Full Text
View/download PDF

14. IC-P-162: RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM

Author

Charil, Arnaud, primary, Schwarz, Adam J., additional, Southekal, Sudeepti, additional, Kotari, Vikas, additional, Navitsky, Michael, additional, Kennedy, Ian, additional, Lu, Ming, additional, Shcherbinin, Sergey, additional, Mintun, Mark A., additional, Devous, Michael D., additional, and Pontecorvo, Michael J., additional

Published
2019
Full Text
View/download PDF

15. P3-322: RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM

Author

Charil, Arnaud, primary, Schwarz, Adam J., additional, Southekal, Sudeepti, additional, Kotari, Vikas, additional, Navitsky, Michael, additional, Kennedy, Ian, additional, Lu, Ming, additional, Shcherbinin, Sergey, additional, Mintun, Mark A., additional, Devous, Michael D., additional, and Pontecorvo, Michael J., additional

Published
2019
Full Text
View/download PDF

16. DT-01-05: TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSY-VALIDATED CASES

Author

Southekal, Sudeepti, primary, Kotari, Vikas, additional, Devous, Michael D., additional, Navitsky, Michael, additional, Kennedy, Ian, additional, Beach, Thomas G., additional, Montine, Thomas J., additional, Arora, Anupa, additional, Flitter, Matthew L., additional, Fleisher, Adam S., additional, Pontecorvo, Michael J., additional, and Mintun, Mark A., additional

Published
2019
Full Text
View/download PDF

18. Tau Positron-Emission Tomography in Former National Football League Players

Author

Stern, Robert A., primary, Adler, Charles H., additional, Chen, Kewei, additional, Navitsky, Michael, additional, Luo, Ji, additional, Dodick, David W., additional, Alosco, Michael L., additional, Tripodis, Yorghos, additional, Goradia, Dhruman D., additional, Martin, Brett, additional, Mastroeni, Diego, additional, Fritts, Nathan G., additional, Jarnagin, Johnny, additional, Devous, Michael D., additional, Mintun, Mark A., additional, Pontecorvo, Michael J., additional, Shenton, Martha E., additional, and Reiman, Eric M., additional

Published
2019
Full Text
View/download PDF

19. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia

Author

Pontecorvo, Michael J, primary, Devous, Michael D, additional, Kennedy, Ian, additional, Navitsky, Michael, additional, Lu, Ming, additional, Galante, Nicholas, additional, Salloway, Stephen, additional, Doraiswamy, P Murali, additional, Southekal, Sudeepti, additional, Arora, Anupa K, additional, McGeehan, Anne, additional, Lim, Nathaniel C, additional, Xiong, Hui, additional, Truocchio, Stephen P, additional, Joshi, Abhinay D, additional, Shcherbinin, Sergey, additional, Teske, Brian, additional, Fleisher, Adam S, additional, and Mintun, Mark A, additional

Published
2019
Full Text
View/download PDF

22. [P2-383]: COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER's DISEASE PATHOLOGY: A PILOT CLINICO-PATHOLOGICAL STUDY

Author

Siderowf, Andrew D., primary, Dirk Keene, C., additional, Beach, Thomas G., additional, Montine, Thomas J., additional, Arora, Anupa, additional, Devous, Michael D., additional, Navitsky, Michael, additional, Kennedy, Ian, additional, Joshi, Abhinay D., additional, Pontecorvo, Michael J., additional, Lu, Ming, additional, Serrano, Geidy E., additional, Rose, Shannon, additional, Wilson, Angela, additional, Hellstern, Leanne, additional, Coleman, Natalie, additional, and Mintun, Mark A., additional

Published
2017
Full Text
View/download PDF

23. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

Author

Fleisher, Adam S., Pontecorvo, Michael J., Devous, Michael D., Lu, Ming, Arora, Anupa K., Truocchio, Stephen P., Aldea, Patricia, Flitter, Matthew, Locascio, Tricia, Devine, Marybeth, Siderowf, Andrew, Beach, Thomas G., Montine, Thomas J., Serrano, Geidy E., Curtis, Craig, Perrin, Allison, Salloway, Stephen, Daniel, Misty, Wellman, Charles, Joshi, Abhinay D., Irwin, David J., Lowe, Val J., Seeley, William W., Ikonomovic, Milos D., Masdeu, Joseph C., Kennedy, Ian, Harris, Thomas, Navitsky, Michael, Southekal, Sudeepti, and Mintun, Mark A.

Abstract

IMPORTANCE: Positron emission tomography (PET) may increase the diagnostic accuracy and confirm the underlying neuropathologic changes of Alzheimer disease (AD). OBJECTIVE: To determine the accuracy of antemortem [18F]flortaucipir PET images for predicting the presence of AD-type tau pathology at autopsy. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study (A16 primary cohort) was conducted from October 2015 to June 2018 at 28 study sites (27 in US sites and 1 in Australia). Individuals with a terminal illness who were older than 50 years and had a projected life expectancy of less than 6 months were enrolled. All participants underwent [18F]flortaucipir PET imaging, and scans were interpreted by 5 independent nuclear medicine physicians or radiologists. Supplemental autopsy [18F]flortaucipir images and pathological samples were also collected from 16 historically collected cases. A second study (FR01 validation study) was conducted from March 26 to April 26, 2019, in which 5 new readers assessed the original PET images for comparison to autopsy. MAIN OUTCOMES AND MEASURES: [18F]flortaucipir PET images were visually assessed and compared with immunohistochemical tau pathology. An AD tau pattern of flortaucipir retention was assessed for correspondence with a postmortem B3-level (Braak stage V or VI) pathological pattern of tau accumulation and to the presence of amyloid-β plaques sufficient to meet the criteria for high levels of AD neuropathological change. Success was defined as having at least 3 of the 5 readers above the lower bounds of the 95% CI for both sensitivity and specificity of 50% or greater. RESULTS: A total of 156 patients were enrolled in the A16 study and underwent [18F]flortaucipir PET imaging. Of these, 73 died during the study, and valid autopsies were performed for 67 of these patients. Three autopsies were evaluated as test cases and removed from the primary cohort (n = 64). Of the 64 primary cohort patients, 34 (53%) were women and 62 (97%) were white; mean (SD) age was 82.5 (9.6) years; and 49 (77%) had dementia, 1 (2%) had mild cognitive impairment, and 14 (22%) had normal cognition. Prespecified success criteria were met for the A16 primary cohort. The flortaucipir PET scans predicted a B3 level of tau pathology, with sensitivity ranging from 92.3% (95% CI, 79.7%-97.3%) to 100.0% (95% CI, 91.0%-100.0%) and specificity ranging from 52.0% (95% CI, 33.5%-70.0%) to 92.0% (95% CI, 75.0%-97.8%). A high level of AD neuropathological change was predicted with sensitivity of 94.7% (95% CI, 82.7%-98.5%) to 100.0% (95% CI, 90.8%-100.0%) and specificity of 50.0% (95% CI, 32.1%-67.9%) to 92.3% (95% CI, 75.9%-97.9%). The FR01 validation study also met prespecified success criteria. Addition of the supplemental autopsy data set and 3 test cases, which comprised a total of 82 patients and autopsies for both the A16 and FR01 studies, resulted in improved specificity and comparable overall accuracy. Among the 156 enrolled participants, 14 (9%) experienced at least 1 treatment-emergent adverse event. CONCLUSIONS AND RELEVANCE: This study’s findings suggest that PET imaging with [18F]flortaucipir could be used to identify the density and distribution of AD-type tau pathology and the presence of high levels of AD neuropathological change, supporting a neuropathological diagnosis of AD.

Published
2020
Full Text
View/download PDF

44. COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER’S DISEASE PATHOLOGY: A PILOT CLINICO-PATHOLOGICAL STUDY

Author

Siderowf, Andrew D., Keene, C. Dirk, Beach, Thomas G., Montine, Thomas J., Arora, Anupa, Devous, Michael D., Sr., Navitsky, Michael, Kennedy, Ian, Joshi, Abhinay D., Pontecorvo, Michael J., Lu, Ming, Serrano, Geidy E., Rose, Shannon, Wilson, Angela, Hellstern, Leanne, Coleman, Natalie, and Mintun, Mark A.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results